Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 safety study of 2-dose ProQuad with recombinant human albumin in young children
NL-OMON31261Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Feb 2008
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of varicella virus vaccine in measles, mumps, rubella and 1 more, sponsored by Sanofi. Primary endpoint: Primary safety endpoint. Started Feb 2008; status: active, not recruiting.
02
Drugs
varicella virus vaccine
03
Conditions
measlesmumpsrubellachickenpox
Beyond the preview
Go deeper on NL-OMON31261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31261.